Conjugate ANY cargo to ANY scaffold to address ANY target
Streamlined Expressed Protein Ligation (SEPL) is a proprietary, versatile, site-specific conjugation platform that enables the development of next-gen biologics, delivering on the promise of maximizing the therapeutic benefit.
Conjugate any cargo to any scaffold.
Connect two separate building blocks. Overcome genetic fusions limitations.
3. TARGETED DELIVERY
Deliver any cargo to the desired cell/tissue in a specific manner.
4. DESIRED FUNCTION.
Cell killing, internalization, stimulation, recruitment.
5. THERAPEUTIC INDEX.
Maximize therapeutic index and other parameters, e.g. half-life.
6. NOVEL COMBINATIONS.
Unlock new value by combining known drugs.
7. NO IMMUNOGENICITY
Traceless conjugation. Scaffold and cargo remain native.
Extremely homogeneous, CMC-reliable product.
Leveraging Ultrafast Split Inteins
Inteins are naturally-occurring, auto-processing domains that edit proteins (so called “protein introns”), by mediating protein splicing in cis. Inteins have been exploited for many years for protein semi-synthesis, e.g. Expressed Protein Ligation (EPL). However, they present some key limitations such as premature intein cleavage, rendering the process uncontrollable, and slow reaction times (days).
ProteoDesign co-founders discovered a new class of inteins, ultrafast split inteins, and developed the company’s proprietary SEPL platform. Unlike other inteins, ultrafast split inteins catalyze protein splicing in trans, conferring significant advantages: intein cleavage is controllable and the reaction occurs in only minutes.
Extremely homogeneous product. Cargo conjugated in a controlled manner.
Plug-n-play platform. Easy to use and no need for re-engineering.
Scaffold and cargo remain native: no unnatural aa, no tags, no glycans altered.
ANY CARGO TO ANY SCAFFOLD
Successfully worked with a wide range of cargos: synthetic peptides, small molecules (cytotoxics, fluorophores) and oligonucleotides, and scaffolds: single-domain antibodies, Fc domains and monoclonal antibodies.